The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Jan 26, 2023. Its latest SEC filing is a 15-12G from Mar 20, 2023.
10-Q for Q3 FY2023, filed Jan 26, 2023
The sections below describe the company as of the FY2022 annual report.
Sells oral medicines for men with advanced prostate cancer and women with heavy menstrual bleeding associated with uterine fibroids.
10-K for FY2022, filed May 11, 2022We are a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering…View ↗
In the U.S., wholesale and specialty distribution and pharmacy customers pay for products when they are delivered. Partners also provide upfront and milestone payments under license and collaboration deals, and Myovant earns royalties on partner product sales.
10-K for FY2022, filed May 11, 2022The Company sells its products in the U.S. principally through wholesale and specialty distribution and pharmacy channels (collectively…View ↗
Since our inception, we have funded our operations primarily from the issuance and sale of our common shares, from debt financing…View ↗
Licenses of intellectual property: If the licenses to intellectual property are determined to be distinct from the other performance…View ↗
$231M
10-K for FY2022, filed May 11, 2022
$231M ↗
In the U.S., wholesale and specialty distributors and pharmacies buy products for resale to healthcare providers and patients. Commercialization partners handle sales in Europe and other international markets.
10-K for FY2022, filed May 11, 2022The Company sells its products in the U.S. principally through wholesale and specialty distribution and pharmacy channels (collectively…View ↗
grow sales of ORGOVYX in the U.S. for the treatment of adult men with advanced prostate cancer; grow sales of MYFEMBREE in the U.S. for the…View ↗
On July 16, 2021, the EC, and on August 9, 2021, the MHRA, approved RYEQO as the first and only long-term, once-daily oral treatment in the…View ↗
On April 29, 2022, the EC approved ORGOVYX as the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate…View ↗
No. It lost $206M in FY2022.
10-K for FY2022, filed May 11, 2022
−$187.3MView ↗
10-K for FY2022, filed May 11, 2022
−$206MView ↗
10-K for FY2022, filed May 11, 2022
−$269.5MView ↗
10-Q for Q3 FY2023, filed Jan 27, 2023
−$57.6MView ↗
8-K, filed Mar 10, 2023
NEW YORK and BASEL, Switzerland, March 10, 2023 -- Sumitovant Biopharma Ltd. (“Sumitovant”) and Myovant Sciences Ltd. (“Myovant”) announced…View ↗
From development to sales
The older report described a clinical-stage company developing relugolix; the latest describes approved ORGOVYX and MYFEMBREE, U.S. product sales, and commercialization through partners.
10-K for FY2019, filed May 24, 2019 10-K for FY2022, filed May 11, 2022OverviewView ↗
Competes with AbbVie, Tolmar Pharmaceuticals, Ferring Pharmaceuticals, Accord BioPharma, and ObsEva
10-K for FY2022, filed May 11, 2022Although ORGOVYX is the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer approved by the FDA…View ↗
Loading...
